FDA commish in demand
This article was originally published in The Gray Sheet
Executive Summary
Senate HELP Committee members urge President Bush to nominate a permanent commissioner "as soon as possible" in Feb. 1 letter. "So that [HHS] Secretary Leavitt can do his job more effectively, you and he need to identify a nominee for FDA commissioner who has demonstrated leadership capabilities, a strong knowledge of science, and an unwavering commitment to promoting and protecting the public health," states the letter, signed by HELP Chair Michael Enzi (R-Wyo.), Ranking Member Ted Kennedy (D-Mass.) and most other committee members. Acting Commissioner Lester Crawford is said to be the President's top candidate for the job (1"The Gray Sheet" Jan. 31, 2005, p. 4)...
You may also be interested in...
FDA Commish Pick Imminent? Crawford Finally May Shed Understudy Role
The White House seems to have selected FDA Acting Commissioner Lester Crawford, PhD/DVM, as its choice to fill the commissioner slot on a permanent basis
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.